[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100356408":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":45,"centralContacts":49,"locations":59,"responsibleParty":76,"collaborators":54,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":54,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":62,"whyStopped":54,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Third Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"ETV group","ACTIVE_COMPARATOR","50 patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day from baseline to life-long.",[13],"Drug: Entecavir",{"label":15,"type":10,"description":16,"interventionNames":17},"TDF group","50 patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day from baseline to life-long.",[18],"Drug: Tenofovir Disoproxil Fumarate",{"label":20,"type":21,"description":22,"interventionNames":23},"TAF group","EXPERIMENTAL","50 patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day from baseline to life-long.",[24],"Drug: Tenofovir Alafenamide",[26,33,39],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Entecavir","Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.",[9],[32],"Baraclude",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Tenofovir Disoproxil Fumarate","Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.",[15],[38],"Viread",{"type":27,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"Tenofovir Alafenamide","Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.",[20],[44],"Vemlidy",[46],{"name":47,"affiliation":5,"role":48},"Liang Peng, Doctor","PRINCIPAL_INVESTIGATOR",[50,56],{"name":51,"role":52,"phone":53,"phoneExt":54,"email":55},"Wenxiong Xu, Doctor","CONTACT","+8613760783281",null,"xwx1983@163.com",{"name":47,"role":52,"phone":57,"phoneExt":54,"email":58},"+8613533978874","pzp33@hotmail.com",[60],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Third Affiliated Hospital of Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510630","China","CN",{"type":69,"coordinates":70},"Point",[71,72],113.25,23.11667,{"lat":72,"lon":71},[75],{"name":47,"role":52,"phone":57,"phoneExt":54,"email":58},{"type":48,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":54,"oldOrganization":54},"Liang Peng","Professer","100356408","three-types-of-nucleotidenucleoside-analogues-treatment-in-hbv-related-aclf-100356408",false,"NCT03920618","Three Types of Nucleotide\u002FNucleoside Analogues Treatment in HBV Related ACLF","Study on Three Types of Nucleotide\u002FNucleoside Analogues Treatment in Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure","HBV","Inclusion Criteria:\n\n1. Positive hepatitis b surface antigen or hepatitis b virus DNA \\> 0.5 year;\n2. Age from 12 to 65 years old;\n3. Serum total bilirubin level \\> 10 times upper limit of normal;\n4. Prothrombin time activity \\\u003C 40% or prothrombin time international ratio \\> 1.5；\n5. Do not receive nucleotide\u002Fnucleoside analogues treatment in the past half year.\n\nExclusion Criteria:\n\n1. Other active liver diseases;\n2. Hepatocellular carcinoma or other malignancy;\n3. Pregnancy or lactation;\n4. Human immunodeficiency virus infection or congenital immune deficiency diseases;\n5. Severe diabetes, autoimmune diseases;\n6. Other important organ dysfunctions;\n7. Using glucocorticoid;\n8. Patients can not follow-up;\n9. Investigator considering inappropriate.","ALL","12 Years","65 Years",{"count":91,"type":92},150,"ESTIMATED","INTERVENTIONAL",[95],"NA","This study is to investigate the clinical efficacy of three types of nucleotide\u002Fnucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.",[98,99],"Hepatitis B","Acute-On-Chronic Liver Failure",[101,102,103,104],"hepatitis b virus","acute-on-chronic liver failure","nucleotide","nucleoside","2024-11-26",{"date":107,"type":108},"2024-11-29","ACTUAL",{"date":110,"type":108},"2019-02-21",{"date":112,"type":92},"2024-12-31",{"name":5,"class":6},1]